Philip J. Barter

The FIELD study - Reply

R. J. Simes, Rona S. Scott, Philip J. Barter, 2006 .

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Jean-Claude Tardif, Frank M. Sacks, Robert A. Hegele, 2018, Nature Reviews Cardiology.

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

James D. Best, Marja-Riitta Taskinen, Philip J. Barter, 2004, Cardiovascular diabetology.

The role of HDL-cholesterol in preventing atherosclerotic disease

Philip J. Barter, P. Barter, 2005 .

Effect of Two Intensive Statin Regimens on Progression of Coronary Disease

Raimund Erbel, Stephen J. Nicholls, Steven E. Nissen, 2011 .

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) Trial (Retraction of vol 59, pg 1778, 2012)

Philip J. Barter, Gilles Lambert, Kerry-Anne Rye, 2013 .

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Philip J. Barter, Heiner Greten, A. Gotto, 2005, The New England journal of medicine.